EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LincRNA-BC7 as a Modulator of Olaparib Sensitivity in Triple-Negative Breast Cancer

Olalekan Olatunde Fadebi iD, Babatunde Adebola Alabi, Richard Khanyile, Zodwa Dlamini iD, Rahaba Marima iD

Epigenomes · 01.06.2026 · 10 (2) · 34

DOI: 10.3390/epigenomes10020034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epigenomes, online erschienen am 01.06.2026. Verfasst von Olalekan Olatunde Fadebi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Health Sciences, Steve Biko Academic Hospital, University of Pretoria, Hatfield, Pretoria 0028, South Afri…. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation, South African Medical Research Council, University of Pretoria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triple-negative breast cancer (TNBC) remains a clinical challenge due to its aggressive nature and the frequent emergence of therapeutic resistance. While the role of protein-coding genes in DNA repair is well-documented, the regulatory contributions of the non-coding genome, specifically long intergenic non-coding RNAs (lincRNAs), remain largely undefined.

Objectives

In this study, we characterize the biological significance of LincRNA-BC7, a novel transcript identified within the breast cancer field effect.

Methods

Through a combined in silico and in vitro approach, we investigated the transcriptional dynamics of the LincRNA-BC7/miR-663a/BRCA1 axis in response to the PARP inhibitor, Olaparib.

Results

Our results demonstrate that Olaparib induces selective cytotoxicity in BRCA1-deficient MDA-MB-231 cells while sparing non-cancerous HEK293 cells, a response accompanied by a significant downregulation of LincRNA-BC7 and a reciprocal upregulation of BRCA1. Bioinformatics analysis through BLASTN, miRBase, and KEGG revealed that LincRNA-BC7 contains highly complementary binding sites for miR-663a, suggesting it functions as a competing endogenous RNA (ceRNA) or “molecular sponge.” Conclusions: By sequestering miR-663a, LincRNA-BC7 appears to modulate the expression of critical signaling nodes within the PI3K-AKT and TP53 pathways, thereby influencing cellular sensitivity to DNA-damaging agents. These findings suggest that LincRNA-BC7 is a key determinant of the aggressive TNBC phenotype and the response to PARP inhibition. Our study establishes the LincRNA-BC7/miR-663a axis as a novel biomarker for precision risk stratification and a promising therapeutic target to enhance treatment outcomes in BRCA1-associated breast cancers.

Schlagwörter

Stichwörter der Autor:innen

BRCA1LincRNA-BC7PARP inhibitionbreast cancerceRNAmiR-663aolaparibtriple-negative breast cancer (TNBC)

Autor:innen und Institutionen

  • Department of Medical Oncology, Faculty of Health Sciences, Steve Biko Academic Hospital, University of Pretoria, Hatfield, Pretoria 0028, South Africa.
  • SAMRC Precision Oncology Research Unit (PORU), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield, Pretoria 0028, South Africa.

ORCID-Profile: Olalekan Olatunde Fadebi, Zodwa Dlamini, Rahaba Marima

Förderung

  • National Research Foundation
  • South African Medical Research Council
  • University of Pretoria

Zitieren

APA

Fadebi, O. O., Alabi, B. A., Khanyile, R., Dlamini, Z., & Marima, R. (2026). LincRNA-BC7 as a Modulator of Olaparib Sensitivity in Triple-Negative Breast Cancer. Epigenomes, 10(2), 34. https://doi.org/10.3390/epigenomes10020034

Vancouver

Fadebi OO, Alabi BA, Khanyile R, Dlamini Z, Marima R. LincRNA-BC7 as a Modulator of Olaparib Sensitivity in Triple-Negative Breast Cancer. Epigenomes. 2026;10(2):34. doi:10.3390/epigenomes10020034

BibTeX
@article{Fadebi2026,
  author = {Fadebi, Olalekan Olatunde and Alabi, Babatunde Adebola and Khanyile, Richard and Dlamini, Zodwa and Marima, Rahaba},
  title = {LincRNA-BC7 as a Modulator of Olaparib Sensitivity in Triple-Negative Breast Cancer},
  journal = {Epigenomes},
  year = {2026},
  volume = {10},
  number = {2},
  pages = {34},
  doi = {10.3390/epigenomes10020034}
}
Kostenlos starten →